Selecta Biosciences (NASDAQ:SELB) announced its quarterly earnings data on Friday. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.75) by $0.10, MarketWatch Earnings reports. The firm had revenue of $0.90 million for the quarter.

Shares of SELB stock opened at $2.17 on Friday. The firm has a market capitalization of $48.76 million, a P/E ratio of -0.68 and a beta of 1.55. Selecta Biosciences has a one year low of $1.41 and a one year high of $16.55.

In other Selecta Biosciences news, Director Amir Nashat acquired 1,166,666 shares of Selecta Biosciences stock in a transaction on Friday, January 25th. The shares were bought at an average price of $1.50 per share, with a total value of $1,749,999.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 25.20% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new position in Selecta Biosciences in the third quarter worth $196,000. Barclays PLC boosted its stake in Selecta Biosciences by 87.6% in the fourth quarter. Barclays PLC now owns 12,661 shares of the company’s stock worth $34,000 after purchasing an additional 5,911 shares in the last quarter. MetLife Investment Advisors LLC acquired a new position in Selecta Biosciences in the third quarter worth $225,000. Virtu Financial LLC acquired a new position in Selecta Biosciences in the third quarter worth $363,000. Finally, Rhumbline Advisers boosted its stake in Selecta Biosciences by 50.3% in the fourth quarter. Rhumbline Advisers now owns 23,802 shares of the company’s stock worth $63,000 after purchasing an additional 7,965 shares in the last quarter. 46.73% of the stock is currently owned by institutional investors.

Several analysts have recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and set a $7.00 price objective on shares of Selecta Biosciences in a report on Friday. Mizuho decreased their price objective on Selecta Biosciences to $4.00 and set a “buy” rating on the stock in a report on Monday, February 4th. Needham & Company LLC decreased their price target on Selecta Biosciences to $12.00 and set a “buy” rating on the stock in a research note on Monday, January 28th. ValuEngine lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Finally, Zacks Investment Research lowered Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, January 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. Selecta Biosciences currently has an average rating of “Hold” and a consensus price target of $15.46.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/selecta-biosciences-selb-releases-quarterly-earnings-results-beats-expectations-by-0-10-eps/2897075.html.

About Selecta Biosciences

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

See Also: Dow Jones Industrial Average (DJIA)

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.